Menu
Search
|

Menu

Close
X

DBV Technologies SA DBVT.OQ (NASDAQ Stock Exchange Global Select Market)

23.02 USD
-0.39 (-1.67%)
As of Feb 23
chart
Previous Close 23.41
Open 23.14
Volume 126,270
3m Avg Volume 147,779
Today’s High 23.18
Today’s Low 22.26
52 Week High 50.40
52 Week Low 20.15
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.56 Mean rating from 9 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Pierre-Henri Benhamou
Chairman of the Board, Chief Executive Officer, Since 2015
Salary: €355,600.00
Bonus: --
David Schilansky
Chief Operating Officer, Since 2015
Salary: --
Bonus: --
Hugh Sampson
Chief Scientific Officer, Since 2015
Salary: --
Bonus: --
Lucie Mondoulet
Director of Research, Since
Salary: --
Bonus: --
Nathalie Donne
Director of Corporate Communication & Business Development, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

177-181 avenue Pierre Brossolett
MONTROUGE     92120

Phone: +331.55427878

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

SPONSORED STORIES